Compare Alcon AG (ALC) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Revvity Inc — how do they compare? Alcon AG trades at $66.92 (market cap $32.69B), while Revvity Inc trades at $108.86 (market cap $12.50B). The key difference: Alcon AG is far larger — about 2.6× Revvity Inc's market cap, and Alcon AG pays the higher dividend (0.54%). Which is the better fit depends on your goals.
| ALC | RVTY | |
|---|---|---|
Market Cap | $32.69B | $12.50B |
Sector | Health | Technology |
52-Week High | $92.22 | $117.75 |
52-Week Low | $62.02 | $82.26 |
Enterprise Value | $36.28B | $14.99B |
Dividend Yield | 0.54% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Revvity (RVTY) trades at $112.95, down 0.71% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent AI integration announcements with Anthropic's Claude platform highlight ongoing innovation in scientific R&D workflows.
The stock presents a mixed outlook with strong earnings performance and AI-driven growth initiatives offset by elevated valuation multiples. Key risks include margin pressure and competitive threats in the life sciences sector. Analyst consensus leans bullish with a $109.38 price target, though current price exceeds this level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
